That’s why it’s our promise to make it accessible and affordable
through insurance and financial assistance

Up to

97%

Insurers who have
coverage for hereditary
cancer testing

Up to

75%

Patients who have $0
for testing at Myriad1

GREATER-THAN

90%

Patients have or will
qualify for a payment of
$100 or less1

Better Coverage:
Because BRACAnalysis CDx® is FDA-approved to identify patients who are or may become eligible for treatment with appropriate targeted therapies, Medicare will cover the testing for appropriate patients with ovarian and breast cancer regardless of family history.

Myriad Promise

If your patients encounter ANY financial hardship
associated with their bill, Myriad will work directly with
them toward their complete satisfaction.

Sources

  1. Internal data on file at Myriad Genetics, Inc.